RxDoctor Payments Data

Christopher Chow, MD

Family Medicine · Broken Arrow, OKNPI 1538111976

Payments from drug & device makers

$8,569in general payments, 2019–2025

Across 527 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$776
  • GSK$693
  • Pfizer$628
  • Bayer$615
  • Abbott$524
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$8,555100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,569 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$121,762
Medicare patients
199
Services billed
2,359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$99,969
MounjaroTirzepatide84$95,075
JardianceEmpagliflozin45$59,066
EliquisApixaban42$49,878
FarxigaDapagliflozin Propanediol15$26,076
XareltoRivaroxaban14$23,991
TenorminAtenolol13$20,461
LinzessLinaclotide30$19,125
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$18,451
KerendiaFinerenone15$17,442
Repatha SureclickEvolocumab20$16,890
TrulicityDulaglutide12$11,362
MyrbetriqMirabegron13$7,818
TrintellixVortioxetine Hydrobromide12$6,429
Atorvastatin Calcium503$6,406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$776$106,43796 claims
Novo NordiskOzempic$1,504$99,96980 claims
Boehringer IngelheimJardiance$59$59,06645 claims
PfizerEliquis$628$49,87842 claims
AstraZenecaFarxiga$332$26,07615 claims
GSKTrelegy Ellipta, Incruse Ellipta, Arnuity Ellipta$693$25,18147 claims
Johnson & JohnsonXarelto$203$23,99114 claims
AbbVieLinzess, Synthroid$501$20,64159 claims
BayerKerendia$615$17,44215 claims
Astellas Pharma US IncMyrbetriq$276$7,81813 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$90$6,42912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Broken Arrow

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →